Kevin Wright


Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLC

January 29th 2021

January 29, 2021 - The combination of pembrolizumab plus concurrent chemoradiation therapy showed antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer, regardless of PD-L1 status or tumor histology.

Pembrolizumab/Lanreotide Combo Confers Antitumor Activity in GEP-NETs

January 15th 2021

January 15, 2021 - Pembrolizumab plus lanreotide elicited a stable disease rate of 39% in patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to findings from the phase 1b/2 PLANET study.

Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple Myeloma

December 5th 2020

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC

May 31st 2020

Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma

May 30th 2020

Treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma.

Tivozanib Showcases Superiority in Relapsed/Refractory RCC

May 29th 2020

Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.